Related references
Note: Only part of the references are listed.Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study
Yoshiki Mikami et al.
CANCER SCIENCE (2013)
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
Elisabeth Luporsi et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy
Nehmat Houssami et al.
EUROPEAN JOURNAL OF CANCER (2012)
Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients
Guo-Chun Zhang et al.
MEDICAL ONCOLOGY (2012)
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
Peter A. Fasching et al.
BMC CANCER (2011)
A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer
H. Jinno et al.
ANNALS OF ONCOLOGY (2010)
Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer
Abigail S. Caudle et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Ki67 in breast cancer: prognostic and predictive potential
Rinat Yerushalmi et al.
LANCET ONCOLOGY (2010)
Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
Priya Rastogi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival
Masakazu Toi et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer
Brian M. Nolen et al.
BREAST CANCER RESEARCH (2008)
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer
C. Natoli et al.
ANNALS OF ONCOLOGY (2007)
Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
R. Leonard et al.
ANNALS OF ONCOLOGY (2006)
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
HD Bear et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
A phase II trial of Neoadjuvant docetaxel and capecitabine for locally advanced breast cancer
PF Lebowitz et al.
CLINICAL CANCER RESEARCH (2004)
Immunohistochemical distinction of invasive from noninvasive breast lesions - A comparative study of p63 versus calponin and smooth muscle myosin heavy chain
RW Werling et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2003)
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results
J O'Shaughnessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
